N, N'-Methylenebisacrylamide Cas: 110-26-9 98% Dawb hmoov
| Catalog Number | xwm 90231 |
| Khoom npe | N, N'-Methylenebisacrylamide |
| CAS | 110-26-9 : kuv |
| Molecular Formula | C7H10N2O2 |
| Molecular Luj | 154.1665 ib |
| Cov ntaub ntawv khaws cia | 2 txog 8 ° C |
| Harmonized tariff Code | 29241900 ib |
Khoom Specification
| Assay | > 98% |
| Dej insoluble | <0.5% |
| Qhov tshwm sim | Dawb hmoov |
| Inorganic sulfates | <0.5% |
| Kev tshawb fawb siv nkaus xwb, tsis yog siv rau tib neeg | kev tshawb fawb siv xwb, tsis yog rau tib neeg siv |
Lub luag haujlwm tseem ceeb ntawm cov qog nqaij hlav fibroblasts (TAF) hauv kev mob qog noj ntshav yog tam sim no pom tseeb hauv cov qog nqaij hlav tsis me me (NSCLC).Txawm li cas los xij, kev kho mob tawm tsam TAFs raug txwv vim tsis muaj kev nkag siab hauv cov txheej txheem tshwj xeeb hauv qab ntawm lawv cov tsub zuj zuj.Ntawm no, cov neeg kho tshuab (piv txwv li, matrix rigidity) thiab soluble mitogenic cues uas tsav lub tsub zuj zuj ntawm TAFs los ntawm loj NSCLC subtypes: adenocarcinoma (ADC) thiab squamous cell carcinoma (SCC) raug dissected.Fibroblasts tau coj mus rau hauv lub substrata engineered los ua kom pom qhov qub- lossis qog-zoo li txhav ntawm cov ntshav ntshav sib txawv, thiab cov txheej txheem tseem ceeb tau piav qhia.Hauv kev tswj cov fibroblasts los ntawm cov ntaub so ntswg nonmalignant, matrix stiffening ib leeg nce fibroblast tsub zuj zuj, thiab qhov kev siv tshuab no yog qhov tseem ceeb los yog piv nrog cov txiaj ntsig loj hlob txog li 0.5% ntshav.Cov stimulatory cues ntawm matrix rigidity tau tsav los ntawm β1 integrin mechano-sensing los ntawm FAK (pY397), thiab tau txuam nrog wit ha posttranscriptionally tsav nce nyob rau hauv β1 integrin qhia.Cov txheej txheem tswj hwm yav dhau los kuj tau pom hauv TAFs tab sis nyob rau hauv ib qho subtype-specific zam, vim SCC-TAFs nthuav tawm ntau dua FAK (pY397), β1 qhia, thiab ERK1/2 (pT202/Y204) dua ADC-TAFs.Ntxiv mus, matrix stiffening induced loj dua TAF tsub zuj zuj nyob rau hauv SCC-TAFs (> 50%) piv nrog ADC-TAFs (10% -20%).Hauv qhov sib piv, SCC-TAFs feem ntau yog cov ntshav desensitized, qhov ADC-TAFs teb rau cov ntshav ntshav siab nkaus xwb.Cov kev tshawb pom no muab thawj cov pov thawj ntawm subtype-specific kev cai ntawm NSCLC-TAF tsub zuj zuj.Tsis tas li ntawd, cov ntaub ntawv no txhawb nqa cov kev kho mob txhawm rau txhawm rau txhim kho lub ntsws elasticity thiab / lossis β1 integrin-dependent mechano kev tswj hwm yuav ua tau zoo rau SCC-TAFs, thaum inhibiting stromal loj hlob qhov taw qhia yuav ua tau zoo tiv thaiv ADC-TAFs.Qhov kev tshawb fawb no nthuav tawm cov txheej txheem sib txawv hauv qab no. qhov txawv txav ntawm cov qog-txhawb fibroblasts nyob rau hauv ob loj subtypes ntawm mob ntsws cancer, uas yuav pab txhim kho kev kho tus kheej tiv thaiv cov hlwb.
